ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

April 1, 2032

Conditions

BAG3 Mutation Associated Dilated Cardiomyopathy

Interventions

DRUG

ALXN2350

ALXN2350 is a gene therapy product consisting of an AAV9 capsid containing BAG3 transgene. It is administered as a single intravenous (IV) infusion.